Genetic Mutation Test Kit
Delivery Restriction
This product cannot be shipped to your selected delivery address/country. Purchase has been disabled.
Product Information
Product Description
Mutations in the epidermal growth factor receptor (EGFR) gene are predictive of the response to EGFR tyrosine kinase inhibitor (TKIs) therapies. The ViennaLab StripAssay® identifies 30 EGFR mutations relevant for non-small cell lung cancer (NSCLC) TKI therapies.
NSCLC comprises approximately 85% of all lung cancers. Tumor specimens from patients should be tested for the presence of EGFR mutations prior to TKI treatment.
Patients carrying EGFR mutations known as `activating mutations´ may benefit from first- or second- or third-generation TKIs. Patients carrying the `resistance mutation´ EGFR T790M may benefit from third-generation TKI.
The EGFR XL StripAssay® is designed to assist clinicians in the stratification of patients considered for TKI therapy.
Additional Information
- • Seller Company: Viennalab Diagnostics
- • Stock Status: In Stock
- • VAT Rate: %20
- • Delivery Status: Select address for delivery eligibility.
